Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 8/10

vs
industry
vs
history
Cash to Debt 0.91
GILD's Cash to Debt is ranked higher than
55% of the 1484 Companies
in the Global Biotechnology industry.

( Industry Median: 48.31 vs. GILD: 0.91 )
GILD' s 10-Year Cash to Debt Range
Min: 0.15   Max: N/A
Current: 0.91

Equity to Asset 0.45
GILD's Equity to Asset is ranked higher than
61% of the 1112 Companies
in the Global Biotechnology industry.

( Industry Median: 0.66 vs. GILD: 0.45 )
GILD' s 10-Year Equity to Asset Range
Min: 0.21   Max: 0.95
Current: 0.45

0.21
0.95
Interest Coverage 37.05
GILD's Interest Coverage is ranked higher than
52% of the 671 Companies
in the Global Biotechnology industry.

( Industry Median: 10000.00 vs. GILD: 37.05 )
GILD' s 10-Year Interest Coverage Range
Min: 5.85   Max: 2509.2
Current: 37.05

5.85
2509.2
F-Score: 8
Z-Score: 7.77
M-Score: -2.26
WACC vs ROIC
8.88%
84.39%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 9/10

vs
industry
vs
history
Operating margin (%) 64.01
GILD's Operating margin (%) is ranked higher than
99% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -82.48 vs. GILD: 64.01 )
GILD' s 10-Year Operating margin (%) Range
Min: -108.08   Max: 61.33
Current: 64.01

-108.08
61.33
Net-margin (%) 51.69
GILD's Net-margin (%) is ranked higher than
98% of the 1186 Companies
in the Global Biotechnology industry.

( Industry Median: -72.15 vs. GILD: 51.69 )
GILD' s 10-Year Net-margin (%) Range
Min: -64.97   Max: 48.62
Current: 51.69

-64.97
48.62
ROE (%) 93.90
GILD's ROE (%) is ranked higher than
99% of the 1364 Companies
in the Global Biotechnology industry.

( Industry Median: -28.35 vs. GILD: 93.90 )
GILD' s 10-Year ROE (%) Range
Min: -49.14   Max: 90.32
Current: 93.9

-49.14
90.32
ROA (%) 44.09
GILD's ROA (%) is ranked higher than
99% of the 1489 Companies
in the Global Biotechnology industry.

( Industry Median: -22.44 vs. GILD: 44.09 )
GILD' s 10-Year ROA (%) Range
Min: -30.31   Max: 42.28
Current: 44.09

-30.31
42.28
ROC (Joel Greenblatt) (%) 491.61
GILD's ROC (Joel Greenblatt) (%) is ranked higher than
99% of the 1448 Companies
in the Global Biotechnology industry.

( Industry Median: -352.58 vs. GILD: 491.61 )
GILD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -127.04   Max: 484.37
Current: 491.61

-127.04
484.37
Revenue Growth (3Y)(%) 41.70
GILD's Revenue Growth (3Y)(%) is ranked higher than
95% of the 808 Companies
in the Global Biotechnology industry.

( Industry Median: 1.30 vs. GILD: 41.70 )
GILD' s 10-Year Revenue Growth (3Y)(%) Range
Min: 5.3   Max: 71.8
Current: 41.7

5.3
71.8
EBITDA Growth (3Y)(%) 55.60
GILD's EBITDA Growth (3Y)(%) is ranked higher than
97% of the 851 Companies
in the Global Biotechnology industry.

( Industry Median: -2.40 vs. GILD: 55.60 )
GILD' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -9.1   Max: 119
Current: 55.6

-9.1
119
EPS Growth (3Y)(%) 60.70
GILD's EPS Growth (3Y)(%) is ranked higher than
98% of the 819 Companies
in the Global Biotechnology industry.

( Industry Median: -4.20 vs. GILD: 60.70 )
GILD' s 10-Year EPS Growth (3Y)(%) Range
Min: -20.6   Max: 153.3
Current: 60.7

-20.6
153.3
» GILD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q2 2014

GILD Guru Trades in Q2 2014

Alan Fournier 2,070,000 sh (New)
Ken Heebner 1,710,000 sh (New)
Joel Greenblatt 466,853 sh (New)
Ken Fisher 975,483 sh (+62.11%)
John Rogers 638,734 sh (+60.78%)
Ray Dalio 349,821 sh (+41.22%)
Julian Robertson 443,911 sh (+28.55%)
Pioneer Investments 3,899,022 sh (+16.40%)
Mario Gabelli 49,170 sh (+11.14%)
RS Investment Management 192,614 sh (+6.88%)
John Burbank 3,774 sh (+4.28%)
First Eagle Investment 400 sh (unchged)
Caxton Associates 100,000 sh (unchged)
George Soros Sold Out
David Rolfe Sold Out
Caxton Associates Sold Out
Louis Moore Bacon Sold Out
Jim Simons 166,648 sh (-11.99%)
Paul Tudor Jones 9,304 sh (-13.89%)
Ronald Muhlenkamp 144,715 sh (-24.63%)
Mariko Gordon 11,654 sh (-35.57%)
Vanguard Health Care Fund 1,633,700 sh (-39.79%)
Jeremy Grantham 10,600 sh (-97.95%)
» More
Q3 2014

GILD Guru Trades in Q3 2014

Louis Moore Bacon 11,734 sh (New)
Dodge & Cox 4,800 sh (New)
David Dreman 2,388 sh (New)
Stanley Druckenmiller 217,500 sh (New)
Paul Tudor Jones 30,245 sh (+225.08%)
John Burbank 12,073 sh (+219.90%)
Ronald Muhlenkamp 206,350 sh (+42.59%)
Joel Greenblatt 664,223 sh (+42.28%)
John Rogers 643,896 sh (+0.81%)
Pioneer Investments 3,536,065 sh (unchged)
First Eagle Investment 400 sh (unchged)
Julian Robertson 443,911 sh (unchged)
Jim Simons Sold Out
Ken Heebner 1,560,000 sh (-8.77%)
Alan Fournier 1,861,000 sh (-10.10%)
Mariko Gordon 10,366 sh (-11.05%)
Mario Gabelli 42,600 sh (-13.36%)
RS Investment Management 151,879 sh (-21.15%)
Ken Fisher 763,423 sh (-21.74%)
Ray Dalio 241,521 sh (-30.96%)
Jeremy Grantham 6,700 sh (-36.79%)
Vanguard Health Care Fund 379,200 sh (-76.79%)
» More
Q4 2014

GILD Guru Trades in Q4 2014

Steven Cohen 1,061,100 sh (New)
Jim Simons 941,400 sh (New)
Leon Cooperman 612,500 sh (New)
First Eagle Investment 1,315,088 sh (+328672.00%)
Paul Tudor Jones 109,372 sh (+261.62%)
John Burbank 37,750 sh (+212.68%)
Ray Dalio 537,321 sh (+122.47%)
Joel Greenblatt 1,009,462 sh (+51.98%)
RS Investment Management 190,460 sh (+25.40%)
John Rogers 802,803 sh (+24.68%)
Julian Robertson 533,911 sh (+20.27%)
Alan Fournier 2,141,000 sh (+15.05%)
Ronald Muhlenkamp 218,945 sh (+6.10%)
Ken Fisher 771,501 sh (+1.06%)
Mario Gabelli 42,600 sh (unchged)
Louis Moore Bacon 50,000 sh (unchged)
First Eagle Investment 1,200 sh (unchged)
Ken Heebner Sold Out
Mariko Gordon Sold Out
Vanguard Health Care Fund Sold Out
Stanley Druckenmiller Sold Out
David Dreman Sold Out
Louis Moore Bacon Sold Out
Dodge & Cox 4,510 sh (-6.04%)
Pioneer Investments 3,180,990 sh (-10.04%)
Jeremy Grantham 4,600 sh (-31.34%)
» More
Q1 2015

GILD Guru Trades in Q1 2015

David Dreman 5,580 sh (New)
John Buckingham 45,281 sh (New)
Lee Ainslie 2,650 sh (New)
Louis Moore Bacon 44,389 sh (New)
Murray Stahl 8,700 sh (New)
NWQ Managers 113,100 sh (New)
Jim Simons 4,032,048 sh (+328.30%)
John Burbank 45,652 sh (+20.93%)
Mario Gabelli 49,470 sh (+16.13%)
John Rogers 891,645 sh (+11.07%)
Joel Greenblatt 1,107,732 sh (+9.73%)
Steven Cohen 1,158,000 sh (+9.13%)
Ken Fisher 789,615 sh (+2.35%)
NWQ Managers 55,200 sh (unchged)
Jeremy Grantham 4,600 sh (unchged)
Leon Cooperman Sold Out
Alan Fournier Sold Out
Ronald Muhlenkamp 218,740 sh (-0.09%)
Pioneer Investments 3,046,688 sh (-4.22%)
Dodge & Cox 4,250 sh (-5.76%)
RS Investment Management 144,820 sh (-23.96%)
Julian Robertson 231,511 sh (-56.64%)
Paul Tudor Jones 6,535 sh (-94.02%)
Ray Dalio 25,221 sh (-95.31%)
First Eagle Investment 400 sh (-99.97%)
» More
» Details

Insider Trades

Latest Guru Trades with GILD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 12.40
GILD's P/E(ttm) is ranked higher than
99% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 12.40 )
GILD' s 10-Year P/E(ttm) Range
Min: 9.69   Max: 45.41
Current: 12.4

9.69
45.41
Forward P/E 9.78
GILD's Forward P/E is ranked higher than
97% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 9.78 )
N/A
PE(NRI) 12.60
GILD's PE(NRI) is ranked higher than
99% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 12.60 )
GILD' s 10-Year PE(NRI) Range
Min: 9.68   Max: 45.49
Current: 12.6

9.68
45.49
P/B 9.70
GILD's P/B is ranked higher than
52% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 6.60 vs. GILD: 9.70 )
GILD' s 10-Year P/B Range
Min: 4.16   Max: 18.59
Current: 9.7

4.16
18.59
P/S 6.50
GILD's P/S is ranked higher than
80% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 40.50 vs. GILD: 6.50 )
GILD' s 10-Year P/S Range
Min: 3.48   Max: 14.41
Current: 6.5

3.48
14.41
PFCF 10.80
GILD's PFCF is ranked higher than
99% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 10.80 )
GILD' s 10-Year PFCF Range
Min: 8.33   Max: 59.09
Current: 10.8

8.33
59.09
POCF 10.57
GILD's POCF is ranked higher than
99% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 10.57 )
GILD' s 10-Year POCF Range
Min: 8.01   Max: 52.27
Current: 10.57

8.01
52.27
EV-to-EBIT 9.36
GILD's EV-to-EBIT is ranked higher than
98% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 9.36 )
GILD' s 10-Year EV-to-EBIT Range
Min: -103.9   Max: 473.4
Current: 9.36

-103.9
473.4
PEG 0.46
GILD's PEG is ranked higher than
100% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 0.46 )
GILD' s 10-Year PEG Range
Min: 0.36   Max: 4.23
Current: 0.46

0.36
4.23
Shiller P/E 35.90
GILD's Shiller P/E is ranked higher than
97% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 35.90 )
GILD' s 10-Year Shiller P/E Range
Min: 17.87   Max: 1840.8
Current: 35.9

17.87
1840.8
Current Ratio 2.70
GILD's Current Ratio is ranked higher than
64% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.40 vs. GILD: 2.70 )
GILD' s 10-Year Current Ratio Range
Min: 1.09   Max: 20.42
Current: 2.7

1.09
20.42
Quick Ratio 2.44
GILD's Quick Ratio is ranked higher than
64% of the 1456 Companies
in the Global Biotechnology industry.

( Industry Median: 4.23 vs. GILD: 2.44 )
GILD' s 10-Year Quick Ratio Range
Min: 0.83   Max: 20.42
Current: 2.44

0.83
20.42
Days Inventory 178.16
GILD's Days Inventory is ranked higher than
83% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 178.16 )
GILD' s 10-Year Days Inventory Range
Min: 148.53   Max: 405.59
Current: 178.16

148.53
405.59
Days Sales Outstanding 64.21
GILD's Days Sales Outstanding is ranked higher than
83% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 143.45 vs. GILD: 64.21 )
GILD' s 10-Year Days Sales Outstanding Range
Min: 65.89   Max: 115.9
Current: 64.21

65.89
115.9

Valuation & Return

vs
industry
vs
history
Price/Tangible Book 32.00
GILD's Price/Tangible Book is ranked lower than
62% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 10.40 vs. GILD: 32.00 )
GILD' s 10-Year Price/Tangible Book Range
Min: 2.08   Max: 131.22
Current: 32

2.08
131.22
Price/DCF (Projected) 1.90
GILD's Price/DCF (Projected) is ranked higher than
97% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 1.90 )
GILD' s 10-Year Price/DCF (Projected) Range
Min: 0.77   Max: 20.81
Current: 1.9

0.77
20.81
Price/Median PS Value 0.70
GILD's Price/Median PS Value is ranked higher than
91% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 3.00 vs. GILD: 0.70 )
GILD' s 10-Year Price/Median PS Value Range
Min: 0.43   Max: 4.91
Current: 0.7

0.43
4.91
Price/Peter Lynch Fair Value 0.50
GILD's Price/Peter Lynch Fair Value is ranked higher than
100% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 0.50 )
GILD' s 10-Year Price/Peter Lynch Fair Value Range
Min: 0.4   Max: 9.13
Current: 0.5

0.4
9.13
Price/Graham Number 4.10
GILD's Price/Graham Number is ranked higher than
92% of the 1652 Companies
in the Global Biotechnology industry.

( Industry Median: 0.00 vs. GILD: 4.10 )
GILD' s 10-Year Price/Graham Number Range
Min: 1.59   Max: 15.08
Current: 4.1

1.59
15.08
Earnings Yield (Greenblatt) 10.90
GILD's Earnings Yield (Greenblatt) is ranked higher than
98% of the 1445 Companies
in the Global Biotechnology industry.

( Industry Median: -5.60 vs. GILD: 10.90 )
GILD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.2   Max: 15
Current: 10.9

0.2
15
Forward Rate of Return (Yacktman) 34.63
GILD's Forward Rate of Return (Yacktman) is ranked higher than
93% of the 188 Companies
in the Global Biotechnology industry.

( Industry Median: 14.83 vs. GILD: 34.63 )
GILD' s 10-Year Forward Rate of Return (Yacktman) Range
Min: 0.2   Max: 46.1
Current: 34.63

0.2
46.1

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, BIIB, CELG, CMXHY » details
Traded in other countries:GIS.Germany, GILD.Mexico, GILD.Switzerland,
Gilead Sciences Inc was incorporated in Delaware on June 22, 1987. The Company is a research-based biopharmaceutical company that discovers, develops and commercializes new medicines for different medical sectors. With each new discovery and experimental drug candidate, it seeks to improve the care of patients suffering from life-threatening diseases around the world. The Company's primary areas of focus include human immunodeficiency virus (HIV)/AIDS, liver diseases such as hepatitis B and C and serious cardiovascular/metabolic and respiratory conditions. The Company has operations in North America, Europe and Australia. It markets products in the HIV/AIDS, liver diseases, respiratory and cardiovascular/metabolic therapeutic areas. The Company's products comprise Truvada is an oral formulation dosed once a day as part of combination therapy to treat human immunodeficiency virus infection in adults. Atripla is an oral formulation dosed once a day for the treatment of HIV infection in adults. Viread is an oral formulation of a nucleotide analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Emtriva is an oral formulation of a nucleoside analogue reverse transcriptase inhibitor, dosed once a day as part of combination therapy to treat HIV infection in adults. Hepsera is an oral formulation of a nucleotide analogue polymerase inhibitor, dosed once a day to treat chronic hepatitis B. AmBisome is a proprietary liposomal formulation of amphotericin B, an antifungal agent to treat serious invasive fungal infections caused by various fungal species. Letairis is an endothelin receptor antagonist indicated for the treatment of pulmonary arterial hypertension in patients with WHO Class II or III symptoms to improve exercise capacity and delay clinical worsening. Ranexa is indicated for the treatment of chronic angina. Vistide is an antiviral medication for the treatment of cytomegalovirus retinitis in patients with AIDS. Cayston is an inhaled antibiotic as a treatment to improve respiratory systems in cystic fibrosis patients with Pseudomonas aeruginosa. The Company has U.S. and international commercial sales operations, with marketing subsidiaries in Australia, Austria, Belgium, Canada, Denmark, Finland, France, Germany, Greece, Ireland, Italy, the Netherlands, New Zealand, Norway, Portugal, Spain, Sweden, Switzerland, Turkey, the United Kingdom and the United States. The Company sells and distributes Truvada, Viread, Emtriva, Hepsera and AmBisome in Asia, Australia, Europe, Latin America, the Middle East and New Zealand either through its commercial teams, third party distributors or corporate partners. The Company's products and development programs target a number of areas, including viral, fungal, respiratory and cardiovascular diseases. The Company's products compete with other available products based mainly on: efficacy; safety; tolerability; acceptance by doctors
» More Articles for GILD

Headlines

Articles On GuruFocus.com
Risk & Reward with Gilead Sciences Inc. (GILD) May 14 2015 
Top-Ranked Analysts Are Bullish on Gilead Sciences, Inc. (GILD) May 14 2015 
8 Top Healthcare Stocks to Watch May 13 2015 
pharma May 10 2015 
Julian Robertson's growing stocks trading at low P/E May 05 2015 
Gilead Sciences Remains a Popular Biotech Stock Following Earnings May 03 2015 
Looking Ahead of Wall Street: Apple, GoPro, Gilead Sciences Apr 27 2015 
AbbVie Focusing On Diversification Routes To Put Higher Sales Numbers On The Board Apr 24 2015 
Weekly CFO Sells Highlight: Gilead Sciences Inc, CarMax Inc, Anthem Inc. Apr 20 2015 
Current positions Apr 13 2015 

More From Other Websites
Who are Gilead Sciences' (GILD) main competitors? May 22 2015
What Does The Johnson & Johnson/Achillion Deal Mean For HCV Competitors? May 21 2015
Will the J&J Deal With Achillion Transform the Hep C Market? May 20 2015
Top 10 stocks of the David Letterman era May 20 2015
Achillion Dives As J&J Hep C Deal Chills Buyout Buzz May 20 2015
Gilead Sciences Inc. (GILD), Yahoo! Inc. (YHOO) and Sinclair Broadcast Group Inc. (SBGI) Among the... May 20 2015
Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
Gilead patents on costly hepatitis C drug challenged in five countries May 20 2015
Gilead patents on costly hepatitis C drug challenged in 5 countries May 20 2015
Soaring Cash Makes Gilead Cheaper Than You Think May 20 2015
UPDATE 1-Achillion partners with J&J to develop hep C drugs (May 19) May 20 2015
High Price for Gilead Sciences Hep C Drug Prompts Patent Challenges May 20 2015
Gilead Sciences: Little Risk From Achillion's Hep-C Partnership With J&J May 20 2015
Move Over Chip Stocks: Here Are 5 Top Biotechs May 20 2015
10 S&P 500 Companies to Have the Biggest Profit Growth in 2015 May 20 2015
Intercept Pharmaceuticals (ICPT) in Focus: Stock Tanks 16.1% - Tale of the Tape May 20 2015
Momentum bargain stocks: TSLA & more May 19 2015
Achillion, J&J To Jointly Develop Hepatitis C Drugs May 19 2015
Healthcare Winners and Losers: May 19, 2015 May 19 2015
Jim Cramer -- Stock Market's Takeover Frenzy Won't End Anytime Soon May 19 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK